For a patient being discharged with antiphospholipid syndrome and splenic thrombosis, how should we transition from low molecular weight heparin (enoxaparin) to warfarin, including the appropriate enoxaparin and warfarin dosing and the recommended duration of anticoagulation?

Transitioning from LMWH to Warfarin in Antiphospholipid Syndrome with Splenic Thrombosis

For a patient with antiphospholipid syndrome (APS) and splenic thrombosis being discharged, start warfarin 2.5-5 mg daily immediately while continuing therapeutic-dose enoxaparin 1 mg/kg subcutaneously every 12 hours, overlap both agents for at least 5 days and until INR is ≥2.0 for two consecutive days, then discontinue enoxaparin and continue warfarin indefinitely targeting INR 2.0-3.0. 1, 2

Dosing Protocol

Enoxaparin Dosing

• Therapeutic dose: 1 mg/kg subcutaneously every 12 hours 1
• Continue this dose throughout the overlap period
• If creatinine clearance <30 mL/min, reduce to 1 mg/kg once daily 3

Warfarin Initiation

• Starting dose: 2.5-5 mg orally once daily 2
• Use the lower end (2.5 mg) for elderly, debilitated patients, or those with potential for increased warfarin sensitivity
• Start warfarin concurrently with enoxaparin—do not wait 1

Overlap Period

Critical timing: Continue both medications for a minimum of 5 days AND until INR reaches ≥2.0 on two consecutive days 1, 2. This dual requirement is essential—meeting only one criterion is insufficient.

• Check INR daily during initial overlap
• Once INR stabilizes in therapeutic range (2.0-3.0), discontinue enoxaparin
• The overlap typically lasts 5-10 days but may extend longer if INR response is delayed

Special Considerations for APS

INR Monitoring Challenges

Important caveat: Lupus anticoagulant (LA), present in many APS patients, can artificially prolong INR measurements, making warfarin monitoring unreliable 4, 5. If your patient is LA-positive:

• Consider chromogenic factor X (CFX) activity monitoring instead of INR, targeting 20-40% activity 5
• Alternatively, use an INR reagent insensitive to lupus anticoagulant
• If neither option is available and INR appears unreliable, consider continuing LMWH long-term rather than transitioning to warfarin 6, 7

Target INR

• Standard target: INR 2.0-3.0 for venous thrombosis in APS 8, 2, 9
• Triple-positive APS patients (positive for all three antibodies: anticardiolipin, anti-β2-glycoprotein I, and lupus anticoagulant) are at highest risk and require meticulous monitoring 9, 10

Duration of Anticoagulation

Indefinite anticoagulation is recommended for APS with thrombosis 1, 8. Specifically:

• Continue warfarin as long as antiphospholipid antibodies persist
• For splanchnic vein thrombosis (which includes splenic thrombosis), anticoagulation is strongly recommended over no anticoagulation 8
• Minimum duration: 3 months, but indefinite therapy is appropriate for APS-related thrombosis 1
• Periodically reassess risk-benefit, but most APS patients require lifelong anticoagulation 9

Practical Discharge Instructions

1. Day 1 of discharge: Patient takes both enoxaparin injection (every 12 hours) and warfarin tablet (once daily, same time each day)
2. INR monitoring: Check INR on day 3, then every 2-3 days until stable in range
3. Stop enoxaparin: Only after ≥5 days overlap AND INR ≥2.0 on two consecutive measurements
4. Long-term warfarin: Continue indefinitely with INR checks every 1-4 weeks once stable 2

Common Pitfalls to Avoid

• Never stop enoxaparin prematurely: Waiting only 5 days without confirming therapeutic INR leaves the patient unprotected
• Don't delay warfarin initiation: Start warfarin immediately, not after several days of enoxaparin alone
• Avoid switching between anticoagulants: Once on warfarin, don't switch back to enoxaparin and vice versa due to increased bleeding risk 11
• Don't ignore LA interference: If INR seems unexpectedly high or low in an LA-positive patient, verify with alternative monitoring methods 4, 5

Alternative: Continuing LMWH Long-Term

If warfarin monitoring proves unreliable due to lupus anticoagulant, or if the patient has recurrent thrombosis on warfarin, continuing enoxaparin 1 mg/kg every 12 hours indefinitely is a valid alternative 6, 10. This approach may be preferable in:

• Triple-positive APS patients
• Those with prior arterial thrombosis
• Patients with unreliable INR monitoring due to LA interference